| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-10-11 | tideglusib | Alzheimer\'s disease |
2b | Noscira, grupo Zeltia (Spain) | Neurodegenerative diseases |
| 2012-10-10 | TroVax® (MVA-5T4) | progressive hormone refractory prostate cancer (HRPC) | 2 | Oxford BioMedica (UK) | Cancer - Oncology |
| 2012-10-10 | Specific anti-H5N1 polyclonal immunoglobulins | H5N1 avian influenza | 1 | Fab’entech (France) | Infectious diseases |
| 2012-10-09 | Unyvero™ System and the Unyvero™ P50 Pneumonia Cartridge | pneumonia respiratory tract infection |
Curetis (Germany) | Infectious diseases - Respiratory diseases | |
| 2012-10-09 | Cx601 (adipose derived allogeneic stem cell therapy) | perianal fistulas in Crohn\'s disease patients | 1-2 | Tigenix (Belgium) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2012-10-09 | Alpha-1 HC aerosol (inhaled formulation of human alpha1-proteinase inhibitor) | cystic fibrosis |
2 | Grifols (Spain) | Rare diseases - Genetic diseases |
| 2012-10-09 | BL-1020 | schizophrenia |
2b | BiolineRx (Israel) | Mental diseases |
| 2012-10-09 | CYT107 (Recombinant human interleukin-7) | patients undergoing T celldepleted (TCD) allogeneic hematopoietic stem cell transplantation (allo-HSCT). | 1 | Cytheris (France) | Transplantation |
| 2012-10-08 | malaria vaccine candidate containing adjuvant Matrix-M™ | malaria |
1 | The Jenner Institute (UK) Isconova (Sweden) | Infectious diseases - Parasitic diseases |
| 2012-10-04 | ZP3022 | diabetes |
preclinical | Zealand Pharma (Denmark) | Metabolic diseases |
| 2012-10-03 | gevokizumab | non-infectious uveitis |
3 | Xoma (USA - CA) | Rare diseases |
| 2012-10-03 | tasquinimod | metastatic castrate-resistant prostate cancer |
2 | Ipsen (France) Active Biotech (Sweden) | Cancer - Oncology |
| 2012-10-02 | eliglustat tartrate | Gaucher disease type 1 |
3 | Genzyme (USA - MA), a Sanofi company (France) | Rare diseases - Genetic diseases |
| 2012-10-02 | insulin degludec | type 2 diabetes | 3 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2012-10-02 | Tradjenta® (linagliptin) | type 2 diabetes | 3 | Boehringer Ingelheim (Germany) Eli Lilly (USA) | Metabolic diseases |
| 2012-10-01 | TASQ (tasquinimod) | castrate resistant prostate cancer |
2 | Active Biotech (Sweden) Ipsen (France) | Cancer - Oncology |
| 2012-10-01 | CV301 (CEA/MUC-1/TRICOM) | metastatic breast cancer | 2 | Bavarian Nordic (Denmark) | Cancer - Oncology |
| 2012-10-01 | AMEP® (targeted biotherapy) | metastatic melanoma |
1 | BioAlliance Pharma (France) | Cancer - Oncology |
| 2012-09-27 | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute attacks of angioedema in patients with Hereditary Angioedema (HAE) | 3 | Pharming (The Netherlands) Santarus (USA) | Genetic diseases - Rare diseases |
| 2012-09-27 | secukinumab (AIN457) | psoriasis |
2 | Novartis (Switzerland) | Autoimmune diseases – Dermatological diseases |
